Status:
COMPLETED
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia
Lead Sponsor:
Cell Genesys
Conditions:
Acute Myelogenous Leukemia
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vacc...
Eligibility Criteria
Inclusion
- Initial diagnosis of de novo AML with no preexisting hematologic dysplasia for more than 3 months.
- No prior therapy except leukapheresis or less than 72 hours of hydroxyurea.
Exclusion
- Prior myelodysplastic disorder, or treatment-related leukemia.
- Prior myeloproliferative disease.
- Acute promyelocytic leukemia (APL).
- Prior chemotherapy for a malignant or nonmalignant disorder.
Key Trial Info
Start Date :
March 1 2001
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00116467
Start Date
March 1 2001
End Date
January 1 2006
Last Update
December 24 2007
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143
2
University of Chicago
Chicago, Illinois, United States, 60637
3
Johns Hopkins University
Baltimore, Maryland, United States, 21231
4
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115